BioArctic Reports Record 2025 Profits Driven by Leqembi Global Expansion

BioArctic has announced record financial results for the full year 2025, marking a significant transition to sustained operating profitability. Net revenues for the fourth quarter reached SEK 184.0 million, a substantial increase from SEK 101.2 million in the same period last year. The company's full-year operating profit exceeded SEK 1.2 billion, bolstered by rising royalties from its Alzheimer’s treatment, Leqembi. During the quarter, the drug secured key regulatory approvals in Brazil, Canada, and the United Kingdom, significantly expanding its global market footprint. Additionally, the US FDA granted Priority Review for the subcutaneous initiation dose of Leqembi Iqlik, potentially simplifying administration for patients. These strong financial milestones, combined with a new partnership with Novartis, underscore BioArctic's strengthening position within the biotechnology sector.